Genistein potentiates the anti-cancer effects of gemcitabine in human osteosarcoma via the downregulation of Akt and nuclear factor-κB pathway

Anti-Cancer Agents in Medicinal Chemistry

Volumn 12, Issue 5, 2012, Pages 554-563

  Liang, Chengzhen ^a   Li, Hao ^a   Shen, Chengchun ^a   Lai, Jianbo ^a   Shi, Zhongli ^a   Liu, Bing ^a   Tao, Hui min ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Akt; Apoptosis; Gemcitabine; Genistein; NF B; Osteosarcoma

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; 3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; GEMCITABINE; GENISTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN KINASE B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NICK END LABELING; NONHUMAN; OSTEOSARCOMA; OSTEOSARCOMA CELL; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR DOWN REGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSMISSION ELECTRON MICROSCOPY; TUMOR CELL LINE; TUMOR GROWTH; TUMOR XENOGRAFT;

EID: 84861662480     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152012800617867     Document Type: Article

References (40)

1. Jain, M.; Arvanitis, C.; Chu, K.; Dewey, W.; Leonhardt, E.; Trinh, M.; Sundberg, C. D.; Bishop, J. M.; Felsher, D. W., Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science. 2002, 297 (5578), 102-104.
2. Shalaby, T.; Hiyama, E.; Grotzer, M. A., Telomere maintenance as therapeutic target in embryonal tumours. Anticance. r Agents. Med. Chem. 2010, 10 (3), 196-212.
3. Conroy, T.; Desseigne, F.; Ychou, M.; Bouche, O.; Guimbaud, R.; Becouarn, Y.; Adenis, A.; Raoul, J. L.; Gourgou-Bourgade, S.; de la Fouchardiere, C.; Bennouna, J.; Bachet, J. B.; Khemissa-Akouz, F.; Pere-Verge, D.; Delbaldo, C.; Assenat, E.; Chauffert, B.; Michel, P.; Montoto-Grillot, C.; Ducreux, M., FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 2011, 364 (19), 1817-1825.
4. Shelley, M.; Cleves, A.; Wilt, T. J.; Mason, M., Gemcitabine for unresectable, locally advanced or metastatic bladder cancer. Cochrane. Database. Syst. Rev. 2011, (4), CD008976.
5. Stemmler, H. J.; diGioia, D.; Freier, W.; Tessen, H. W.; Gitsch, G.; Jonat, W.; Brugger, W.; Kettner, E.; Abenhardt, W.; Tesch, H.; Hurtz, H. J.; Rosel, S.; Brudler, O.; Heinemann, V., Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer. Br. J. Cancer. 2011, 104 (7), 1071-1078.
6. Zanellato, I.; Boidi, C. D.; Lingua, G.; Betta, P. G.; Orecchia, S.; Monti, E.; Osella, D., In vitro anti-mesothelioma activity of cisplatin-gemcitabine combinations: evidence for sequencedependent effects. Cancer. Chemother. Pharmacol. 2011, 67 (2), 265-273.
7. Specenier, P. M.; Weyler, J.; Van Laer, C.; Van den Weyngaert, D.; Van den Brande, J.; Huizing, M. T.; Altintas, S.; Vermorken, J. B., A non-randomized comparison of gemcitabine-based chemoradiation with or without induction chemotherapy for locally advanced squamous cell carcinoma of the head and neck. Bmc. Cancer. 2009, 9, 273.
8. Greenhalf, W.; Thomas, A., Combination therapy for the treatment of pancreatic cancer. Anticancer. Agents. Med. Chem. 2011, 11 (5), 418-426.
9. Fehlauer, F.; Muench, M.; Smid, E. J.; Slotman, B.; Richter, E.; Van der Valk, P.; Sminia, P., Combined modality therapy of gemcitabine and irradiation on human glioma spheroids derived from cell lines and biopsy tissue. Oncol. Rep. 2006, 15(1), 97-105.
10. Ando, T.; Ichikawa, J.; Okamoto, A.; Tasaka, K.; Nakao, A.; Hamada, Y., Gemcitabine inhibits viability, growth, and metastasis of osteosarcoma cell lines. J. Orthop. Res. 2005, 23 (4), 964-969.
11. Leu, K. M.; Ostruszka, L. J.; Shewach, D.; Zalupski, M.; Sondak, V.; Biermann, J. S.; Lee, J. S.; Couwlier, C.; Palazzolo, K.; Baker, L. H., Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. J. Clin. Oncol. 2004, 22 (9), 1706-1712.
12. Dileo, P.; Morgan, J. A.; Zahrieh, D.; Desai, J.; Salesi, J. M.; Harmon, D. C.; Quigley, M. T.; Polson, K.; Demetri, G. D.; George, S., Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: results of a phase II trial. Cancer. 2007, 109 (9), 1863-1869.
13. Assifi, M. M.; Hines, O. J., Anti-angiogenic agents in pancreatic cancer: a review. Anticancer Agents Med. Chem. 2011, 11 (5), 464-469.
14. Nakanishi, C.; Toi, M., Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat. Rev. Cancer. 2005, 5 (4), 297-309.
15. Banerjee, S.; Li, Y.; Wang, Z.; Sarkar, F. H., Multi-targeted therapy of cancer by genistein. Cancer. Lett. 2008, 269 (2), 226-242.
16. Lee, S. H.; Ryu, J. K.; Lee, K. Y.; Woo, S. M.; Park, J. K.; Yoo, J. W.; Kim, Y. T.; Yoon, Y. B., Enhanced anti-tumor effect of combination therapy with gemcitabine and apigenin in pancreatic cancer. Cancer. Lett. 2008, 259 (1), 39-49.
17. Zhang, B.; Shi, Z. L.; Liu, B.; Yan, X. B.; Feng, J.; Tao, H. M., Enhanced anticancer effect of gemcitabine by genistein in osteosarcoma: the role of Akt and nuclear factor-kappaB. Anticancer. Drugs. 2010, 21 (3), 288-296.
18. Liang, C. Z.; Zhang, J. K.; Shi, Z.; Liu, B.; Shen, C. Q.; Tao, H. M., Matrine induces caspase-dependent apoptosis in human osteosarcoma cells in vitro and in vivo through the upregulation of Bax and Fas/FasL and downregulation of Bcl-2. Cancer. Chemother. Pharmacol. 2011.
19. Gessner, P. K., Isobolographic analysis of interactions: an update on applications and utility. Toxicology. 1995, 105 (2-3), 161-179.
20. Briccoli, A.; Rocca, M.; Salone, M.; Guzzardella, G. A.; Balladelli, A.; Bacci, G., High grade osteosarcoma of the extremities metastatic to the lung: long-term results in 323 patients treated combining surgery and chemotherapy, 1985-2005. Surg. Oncol. 2010, 19 (4), 193-199.
21. Barnes, S., Evolution of the health benefits of soy isoflavones. Proc. Soc. Exp. Biol. Med. 1998, 217 (3), 386-392.
22. Li, Y.; Ellis, K. L.; Ali, S.; El-Rayes, B. F.; Nedeljkovic-Kurepa, A.; Kucuk, O.; Philip, P. A.; Sarkar, F. H., Apoptosis-inducing effect of chemotherapeutic agents is potentiated by soy isoflavone genistein, a natural inhibitor of NF-kappaB in BxPC-3 pancreatic cancer cell line. Pancreas. 2004, 28 (4), e90-95.
23. Morris, C.; Thorpe, J.; Ambrosio, L.; Santin, M., The soybean isoflavone genistein induces differentiation of MG63 human osteosarcoma osteoblasts. J. Nutr. 2006, 136 (5), 1166-1170.
24. Bensassi, F.; El Golli-Bennour, E.; Abid-Essefi, S.; Bouaziz, C.; Hajlaoui, M. R.; Bacha, H., Pathway of deoxynivalenol-induced apoptosis in human colon carcinoma cells. Toxicology. 2009, 264 (1-2), 104-109.
25. Falasca, M.; Selvaggi, F.; Buus, R.; Sulpizio, S.; Edling, C. E., Targeting phosphoinositide 3-kinase pathways in pancreatic cancer-from molecular signalling to clinical trials. Anticancer. Agents. Med. Chem. 2011, 11 (5), 455-463.
26. Kawauchi, K.; Ogasawara, T.; Yasuyama, M.; Otsuka, K.; Yamada, O., Regulation and importance of the PI3K/Akt/mTOR signaling pathway in hematologic malignancies. Anticancer. Agents. Med. Chem. 2009, 9 (9), 1024-1038.
27. Neergheen, V. S.; Bahorun, T.; Taylor, E. W.; Jen, L. S.; Aruoma, O. I., Targeting specific cell signaling transduction pathways by dietary and medicinal phytochemicals in cancer chemoprevention. Toxicology. 2010, 278 (2), 229-241.
28. Romashkova, J. A.; Makarov, S. S., NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature. 1999, 401 (6748), 86-90.
29. Ozes, O. N.; Mayo, L. D.; Gustin, J. A.; Pfeffer, S. R.; Pfeffer, L. M.; Donner, D. B., NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature. 1999, 401 (6748), 82-85.
30. Bacci, G.; Ferrari, S.; Bertoni, F.; Ruggieri, P.; Picci, P.; Longhi, A.; Casadei, R.; Fabbri, N.; Forni, C.; Versari, M.; Campanacci, M., Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report. J. Clin. Oncol. 2000, 18 (24), 4016-4027.
31. Liu, B.; Shi, Z. L.; Feng, J.; Tao, H. M., Celecoxib, a cyclooxygenase-2 inhibitor, induces apoptosis in human osteosarcoma cell line MG-63 via down-regulation of PI3K/Akt. Cell. Biol. Int. 2008, 32 (5), 494-501.
32. Shishodia, S.; Aggarwal, B. B., Nuclear factor-kappaB activation: a question of life or death. J Biochem Mol. Biol. 2002, 35 (1), 28-40.
33. Telliez, A.; Furman, C.; Pommery, N.; Henichart, J. P., Mechanisms leading to COX-2 expression and COX-2 induced tumorigenesis: topical therapeutic strategies targeting COX-2 expression and activity. Anticancer. Agents. Med. Chem. 2006, 6 (3), 187-208.
34. Banerjee, S.; Zhang, Y.; Ali, S.; Bhuiyan, M.; Wang, Z.; Chiao, P. J.; Philip, P. A.; Abbruzzese, J.; Sarkar, F. H., Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. Cancer. Res. 2005, 65 (19), 9064-9072.
35. Banerjee, S.; Zhang, Y.; Wang, Z.; Che, M.; Chiao, P. J.; Abbruzzese, J. L.; Sarkar, F. H., In vitro and in vivo molecular evidence of genistein action in augmenting the efficacy of cisplatin in pancreatic cancer. Int. J. Cancer. 2007, 120 (4), 906-917.
36. Sarkar, F. H.; Li, Y., Using chemopreventive agents to enhance the efficacy of cancer therapy. Cancer. Res. 2006, 66 (7), 3347-3350.
37. Chalmers, A. J., Overcoming resistance of glioblastoma to conventional cytotoxic therapies by the addition of PARP inhibitors. Anticancer. Agents. Med. Chem. 2010, 10 (7), 520-533.
38. Weisburg, J. H.; Schuck, A. G.; Silverman, M. S.; Ovits-Levy, C. G.; Solodokin, L. J.; Zuckerbraun, H. L.; Babich, H., Pomegranate extract, a prooxidant with antiproliferative and proapoptotic activities preferentially towards carcinoma cells. Anticancer. Agents. Med. Chem. 2010, 10 (8), 634-644.
39. Barbie, D. A.; Tamayo, P.; Boehm, J. S.; Kim, S. Y.; Moody, S. E.; Dunn, I. F.; Schinzel, A. C.; Sandy, P.; Meylan, E.; Scholl, C.; Frohling, S.; Chan, E. M.; Sos, M. L.; Michel, K.; Mermel, C.; Silver, S. J.; Weir, B. A.; Reiling, J. H.; Sheng, Q.; Gupta, P. B.; Wadlow, R. C.; Le, H.; Hoersch, S.; Wittner, B. S.; Ramaswamy, S.; Livingston, D. M.; Sabatini, D. M.; Meyerson, M.; Thomas, R. K.; Lander, E. S.; Mesirov, J. P.; Root, D. E.; Gilliland, D. G.; Jacks, T.; Hahn, W. C., Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 2009, 462 (7269), 108-112.
40. Kogel, D.; Fulda, S.; Mittelbronn, M., Therapeutic exploitation of apoptosis and autophagy for glioblastoma. Anticancer. Agents. Med. Chem. 2010, 10 (6), 438-449.